Carlson Capital L P Coherus Bio Sciences, Inc. Transaction History

Carlson Capital L P

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$14.43 - $19.16 $331,890 - $440,680	-23,000 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$11.67 - $22.53 $752,715 - $1.45 Million	-64,500 Reduced 73.71%	23,000 $373,000
Q4 2019 Feb 14, 2020	BUY	$16.33 - $21.37 $478,077 - $625,628	29,276 Added 50.28%	87,500 $1.58 Million
Q3 2019 Nov 13, 2019	SELL	$16.3 - $23.37 $1.58 Million - $2.26 Million	-96,776 Reduced 62.44%	58,224 $1.18 Million
Q2 2019 Aug 12, 2019	SELL	$13.1 - $22.1 $4.46 Million - $7.52 Million	-340,365 Reduced 68.71%	155,000 $3.43 Million
Q1 2019 May 14, 2019	SELL	$8.38 - $15.5 $10.3 Million - $19 Million	-1,224,171 Reduced 71.19%	495,365 $6.76 Million
Q4 2018 Feb 13, 2019	BUY	$8.65 - $16.28 $14.9 Million - $28 Million	1,719,536 New	1,719,536 $15.6 Million
Q4 2017 Feb 14, 2018	SELL	$8.35 - $14.4 $6.08 Million - $10.5 Million	-728,419 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$11.1 - $14.5 $8.09 Million - $10.6 Million	728,419	728,419 $9.72 Million

132

76.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $91.7M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Carlson Capital L P, based on Form 13F filings with the SEC.

Stay updated on Carlson Capital L P with notifications on news.